ArticleMolecular cancer therapeutics2022

Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian Cancer.

Shoumei Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.